Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
BUSINESS
Meiji Pharma Eyes Japan Filing of Arcturus’ COVID Vaccine Next Spring
Meiji Seika Pharma is looking to file Arcturus Therapeutics’ next-generation mRNA vaccine in Japan in the spring of 2023 with an eye towards summer approval. The drug maker is currently in talks with the US biotech to in-license the vaccine,…
To read the full story
Related Article
- Meiji Launches Japan PIII of mRNA COVID Shot for BA.4/5 Strain
October 3, 2023
- Meiji Seeks Booster Nod for COVID-19 mRNA Vaccine in Japan
July 3, 2023
- Meiji Files CSL Seqirus’ mRNA COVID Vaccine in Japan
May 1, 2023
- Meiji/CSL Seqirus Tie Up for Sales of COVID-19 mRNA Vaccine in Japan
April 12, 2023
- Mejii Kicks Off Japan PIII for Arcturus’ COVID mRNA Vaccine
December 14, 2022
- Meiji Pharma in Talks on Japan Rights to Arcturus’ COVID Jab Candidate
August 26, 2022
- Meiji Pharma/KM Biologics Eager to Acquire mRNA Vaccine, Mull Collabs with Upstarts and Academia
July 7, 2022
- mRNA CDMO Arcalis Aims for One Stop Provider for Seed Verification, R&D, Commercial Production
May 31, 2021
BUSINESS
- Eylea Bio-AG to Carry DME Indication Missing from Fuji’s Biosimilar Label
December 5, 2025
- Forxiga Generics Launch in Japan at 33.6% of Originator Price: Sawai, T’s Pharma
December 5, 2025
- Vimpat Copies Hit Shelves at 35% of Originator Price as 10 Firms Flock to Market
December 5, 2025
- Keytruda Extends Japan Sales Lead to 26 Straight Months in November: Encise
December 5, 2025
- Meiji Pharma Takes Stake in Lyric Bio to Back Next-Gen IVIg Manufacturing
December 5, 2025
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…